US combination office stalled pending procedural steps
This article was originally published in Clinica
Executive Summary
Setting up the FDA's new office of combination products within the commissioner's office in December 2002 was the agency's first step towards putting the new user fee bill in place. But the office will not be fully operational until the FDA can draft regulations spelling out certain office procedures, according to its first director, Mark Kramer.